(ACAD) ACADIA Pharmaceuticals - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.805m USD | Total Return: 54.1% in 12m
Antipsychotic, Trofinetide, Neurology, Psychosis, Rett Syndrome
Total Rating 34
Safety 28
Buy Signal -0.26
Biotechnology
Industry Rotation: -3.7
Industry Rotation: -3.7
Market Cap:
3.81B
Avg Turnover: 36.7M USD
Avg Turnover: 36.7M USD
ATR:
3.68%
Peers RS (IBD): 21.8
Peers RS (IBD): 21.8
Risk 5d forecast
Volatility44.8%
Rel. Tail Risk-15.2%
Reward TTM
Sharpe Ratio0.93
Alpha11.57
Character TTM
Beta1.123
Beta Downside2.637
Drawdowns 3y
Max DD57.87%
CAGR/Max DD0.11
EPS (Earnings per Share)
EPS CAGR: 20.30%
EPS Trend: 59.1%
EPS Trend: 59.1%
Last SUE: -0.24
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 27.12%
Rev. Trend: 93.0%
Rev. Trend: 93.0%
Last SUE: -1.52
Qual. Beats: 0
Qual. Beats: 0
Warnings
Altman Z'' -5.67 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Description: ACAD ACADIA Pharmaceuticals
ACADIA Pharmaceuticals (NASDAQ: ACAD) is a U.S. biopharma focused on central nervous system (CNS) disorders and rare diseases, commercializing NUPLAZID for Parkinson’s disease psychosis and advancing a pipeline that includes DAYBUE for Rett syndrome and multiple phase-III candidates such as pimavanserin for schizophrenia-related negative symptoms.
Recent financials show FY 2025 revenue of $150 million, driven primarily by NUPLAZID sales, and a cash-and-equivalents balance of $620 million, giving the company an estimated 18-month runway without additional financing.
Key sector drivers remain strong: the aging U.S. population is expanding the addressable market for CNS therapeutics, while the FDA’s accelerated-approval pathways for rare neuro-developmental diseases are encouraging faster commercial timelines.
Investors looking for deeper insight may want to explore ValueRay’s analytical platform for a more granular view of ACAD’s valuation metrics.
- NUPLAZID sales growth impacts revenue from Parkinsons disease psychosis
- DAYBUE adoption drives revenue in Rett syndrome market
- Clinical trial success for pipeline drugs expands future revenue streams
- Regulatory approval risks affect new drug commercialization
- Competition from new neurological treatments could limit market share
Piotroski VR‑10 (Strict)
3.5
| Net Income: 391.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -6.51 > 1.0 |
| NWC/Revenue: 73.26% < 20% (prev 56.74%; Δ 16.52% < -1%) |
| CFO/TA 0.07 > 3% & CFO 109.8m > Net Income 391.0m |
| Net Debt (-767.5m) to EBITDA (131.4m): -5.84 < 3 |
| Current Ratio: 3.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (171.4m) vs 12m ago 3.00% < -2% |
| Gross Margin: 91.69% > 18% (prev 0.91%; Δ 9.08k% > 0.5%) |
| Asset Turnover: 77.87% > 50% (prev 80.64%; Δ -2.77% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z''
-5.67
| A: 0.50 (Total Current Assets 1.06b - Total Current Liabilities 277.1m) / Total Assets 1.56b |
| B: -1.16 (Retained Earnings -1.81b / Total Assets 1.56b) |
| C: 0.07 (EBIT TTM 96.3m / Avg Total Assets 1.38b) |
| D: -5.38 (Book Value of Equity -1.81b / Total Liabilities 336.8m) |
| Altman-Z'' Score: -5.67 = D |
Beneish M
-2.12
| DSRI: 1.27 (Receivables 148.2m/104.7m, Revenue 1.07b/957.8m) |
| GMI: 1.00 (GM 91.69% / 91.46%) |
| AQI: 1.71 (AQ_t 0.29 / AQ_t-1 0.17) |
| SGI: 1.12 (Revenue 1.07b / 957.8m) |
| TATA: 0.18 (NI 391.0m - CFO 109.8m) / TA 1.56b) |
| Beneish M-Score: -2.12 (Cap -4..+1) = BB |
What is the price of ACAD shares?
As of April 12, 2026, the stock is trading at USD 21.74 with a total of 822,399 shares traded.
Over the past week, the price has changed by -2.60%, over one month by -3.55%, over three months by -18.24% and over the past year by +54.08%.
Over the past week, the price has changed by -2.60%, over one month by -3.55%, over three months by -18.24% and over the past year by +54.08%.
Is ACAD a buy, sell or hold?
ACADIA Pharmaceuticals has received a consensus analysts rating of 3.95.
Therefore, it is recommended to buy ACAD.
- StrongBuy: 7
- Buy: 6
- Hold: 6
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the ACAD price?
| Analysts Target Price | 31.9 | 46.5% |
ACADIA Pharmaceuticals (ACAD) - Fundamental Data Overview
as of 08 April 2026
P/E Trailing = 9.7043 P/E Forward = 51.0204
P/S = 3.5515
P/B = 3.0838
P/EG = 50.8642
Revenue TTM = 1.07b USD
EBIT TTM = 96.3m USD
EBITDA TTM = 131.4m USD
Long Term Debt = 52.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 11.6m USD (from shortTermDebt, last quarter)
Debt = 52.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -767.5m USD (recalculated: Debt 52.2m - CCE 819.7m)
Enterprise Value = 3.04b USD (3.81b + Debt 52.2m - CCE 819.7m)
Interest Coverage Ratio = unknown (Ebit TTM 96.3m / Interest Expense TTM 0.0)
EV/FCF = 28.89x (Enterprise Value 3.04b / FCF TTM 105.1m)
FCF Yield = 3.46% (FCF TTM 105.1m / Enterprise Value 3.04b)
FCF Margin = 9.81% (FCF TTM 105.1m / Revenue TTM 1.07b)
Net Margin = 36.49% (Net Income TTM 391.0m / Revenue TTM 1.07b)
Gross Margin = 91.69% ((Revenue TTM 1.07b - Cost of Revenue TTM 89.0m) / Revenue TTM)
Gross Margin QoQ = 90.77% (prev 92.23%)
Tobins Q-Ratio = 1.94 (Enterprise Value 3.04b / Total Assets 1.56b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 52.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = 76.0m (EBIT 96.3m * (1 - 21.00%))
Current Ratio = 3.83 (Total Current Assets 1.06b / Total Current Liabilities 277.1m)
Debt / Equity = 0.04 (Debt 52.2m / totalStockholderEquity, last quarter 1.23b)
Debt / EBITDA = -5.84 (Net Debt -767.5m / EBITDA 131.4m)
Debt / FCF = -7.30 (Net Debt -767.5m / FCF TTM 105.1m)
Total Stockholder Equity = 933.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 28.42% (Net Income 391.0m / Total Assets 1.56b)
RoE = 41.90% (Net Income TTM 391.0m / Total Stockholder Equity 933.1m)
RoCE = 9.77% (EBIT 96.3m / Capital Employed (Equity 933.1m + L.T.Debt 52.2m))
RoIC = 8.15% (NOPAT 76.0m / Invested Capital 933.1m)
WACC = 9.80% (E(3.81b)/V(3.86b) * Re(9.93%) + D(52.2m)/V(3.86b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.93% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.45%
[DCF] Terminal Value 62.97% ; FCFF base≈126.0m ; Y1≈82.7m ; Y5≈37.8m
[DCF] Fair Price = 7.85 (EV 570.5m - Net Debt -767.5m = Equity 1.34b / Shares 170.5m; r=9.80% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 59.07 | EPS CAGR: 20.30% | SUE: -0.24 | # QB: 0
Revenue Correlation: 92.99 | Revenue CAGR: 27.12% | SUE: -1.52 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.12 | Chg7d=+0.002 | Chg30d=+0.006 | Revisions Net=-6 | Analysts=10
EPS current Year (2026-12-31): EPS=0.50 | Chg7d=-0.001 | Chg30d=+0.007 | Revisions Net=-8 | Growth EPS=-40.3% | Growth Revenue=+16.5%
EPS next Year (2027-12-31): EPS=0.90 | Chg7d=+0.000 | Chg30d=+0.012 | Revisions Net=-2 | Growth EPS=+82.5% | Growth Revenue=+11.6%
[Analyst] Revisions Ratio: -1.00 (0 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -0.4% (Discount Rate 9.9% - Earnings Yield 10.3%)
[Growth] Growth Spread = +15.7% (Analyst 15.3% - Implied -0.4%)
External Resources